| Mr Thomas J Negri, ANP | |
|
9101 Ravenscroft Rd, Clifton, NJ 07013-2727 | |
| (973) 246-5413 | |
| (973) 246-5413 |
| Full Name | Mr Thomas J Negri |
|---|---|
| Gender | Male |
| Speciality | Registered Nurse - Medical-surgical |
| Location | 9101 Ravenscroft Rd, Clifton, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033487152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WM0705X | Registered Nurse - Medical-surgical | 26NR11976900 (New Jersey) | Primary |
| Entity Name | North Haledon Medical, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624088 PECOS PAC ID: 0345299947 Enrollment ID: O20050121000032 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Ipc Hospitalist Physicians Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639303159 PECOS PAC ID: 2769533165 Enrollment ID: O20090625000023 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Integrative Functional Medicine Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063739829 PECOS PAC ID: 1951434240 Enrollment ID: O20100806000769 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Sovereign Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710282082 PECOS PAC ID: 1456535392 Enrollment ID: O20110418000519 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Two River Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417354333 PECOS PAC ID: 0648594820 Enrollment ID: O20150116000462 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Liberty Med Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366983033 PECOS PAC ID: 7416234075 Enrollment ID: O20170509000044 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Entity Name | Passaic River Observation, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568113348 PECOS PAC ID: 0143617126 Enrollment ID: O20220421000141 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Thomas J Negri, ANP 9101 Ravenscroft Rd, Clifton, NJ 07013-2727 Ph: (973) 246-5413 | Mr Thomas J Negri, ANP 9101 Ravenscroft Rd, Clifton, NJ 07013-2727 Ph: (973) 246-5413 |
News Archive
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
› Verified 1 days ago
Sandra Kankam, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 67 Whiteweld Ter, Clifton, NJ 07013 Phone: 718-671-2100 | |
Eunice O Bamgbade, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 404 Clifton Ave, Clifton, NJ 07011 Phone: 856-426-9520 | |
Mrs. Nancy Catherine O'brien, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Bloomfield Ave, Clifton, NJ 07012 Phone: 973-594-0125 Fax: 973-594-0536 | |
Myleen Mamaril, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1 Ward Ave, Clifton, NJ 07014 Phone: 862-264-3740 | |
Ms. Marjorie Amanda Greene, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 98 Viola Ave, Clifton, NJ 07011 Phone: 973-246-3370 Fax: 973-246-3370 | |
Janet Levy-robinson, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 65 3rd St, Apt H1, Clifton, NJ 07011 Phone: 201-336-2930 |